Independent Research Analysts Give Bayer (BAYN) a €69.00 Price Target

Independent Research set a €69.00 ($80.23) target price on Bayer (FRA:BAYN) in a research report released on Friday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research analysts have also weighed in on BAYN. HSBC set a €104.00 ($120.93) price objective on Bayer and gave the stock a neutral rating in a research report on Monday, August 13th. Goldman Sachs Group set a €116.00 ($134.88) price objective on Bayer and gave the stock a buy rating in a research report on Monday, August 13th. Barclays set a €110.00 ($127.91) price objective on Bayer and gave the stock a buy rating in a research report on Monday, August 13th. Commerzbank set a €111.00 ($129.07) price objective on Bayer and gave the stock a buy rating in a research report on Monday, August 13th. Finally, JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on Bayer and gave the stock a buy rating in a research report on Monday, August 13th. Seven equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of €92.48 ($107.53).

BAYN stock opened at €64.58 ($75.09) on Friday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: What is a capital gain?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit